- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00602615
Bioequivalency Study of Torsemide Tablets Under Fed Conditions
January 19, 2018 updated by: Roxane Laboratories
A Single Dose, Two-Period, Two-Treatment, Two-Way Crossover Bioequivalency Study of 20 mg Torsemide Tablets Under Fed Conditions
The objective of this study was the bioequivalence of a Roxane Laboratories' Torsemide Tablets, 20 mg, to Demadex® Tablets, 20 mg (Roche) under fed conditions using a single-dose, 2-treatment, 2-period, crossover design.
Study Overview
Study Type
Interventional
Enrollment (Actual)
28
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Missouri
-
Springfield, Missouri, United States, 65801
- Bio-Kinetic Clinical Applications, Inc.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 45 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- No clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening.
Exclusion Criteria:
- Positive test for HIV, Hepatitis B, or Hepatitis C.
- Treatment with known enzyme altering drugs.
- History of allergic or adverse response to Torsemide or any comparable or similar product.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Bioequivalence
Time Frame: Baseline, Two period, Seven day washout
|
Baseline, Two period, Seven day washout
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Dennis Morrison, DO, Bio-Kinetic Clinical Applications, Inc.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2003
Primary Completion (Actual)
September 1, 2003
Study Completion (Actual)
September 1, 2003
Study Registration Dates
First Submitted
January 15, 2008
First Submitted That Met QC Criteria
January 25, 2008
First Posted (Estimate)
January 28, 2008
Study Record Updates
Last Update Posted (Actual)
January 23, 2018
Last Update Submitted That Met QC Criteria
January 19, 2018
Last Verified
January 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TORE-02
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Edema
-
Eye-yon MedicalCompletedCORNEAL EDEMAIsrael, Poland
-
Federico II UniversityCompletedPseudophakic Cystoid Macular Edema
-
California Retina ConsultantsRegeneron PharmaceuticalsCompletedDiabetic Macular Edema | Cystoid Macular EdemaUnited States
-
Postgraduate Institute of Medical Education and...CompletedDiabetic Macular Edema | Vision Disorders | Macular Edema, Cystoid | Clinically Significant Macular EdemaIndia
-
National Cardiovascular Center Harapan Kita Hospital...CompletedMyocardial Edema
-
OcugenNot yet recruitingDiabetic Macular Edema | Center Involved Diabetic Macular Edema
-
Eye-yon MedicalCompletedChronic Cornel EdemaNetherlands, Israel, Germany, Spain
-
University of RochesterNeuroMetrix, Inc.Active, not recruiting
-
Luca MarinEnrolling by invitation
Clinical Trials on Torsemide
-
Sarfez Pharmaceuticals, Inc.RecruitingHeart Failure | Overactive Bladder | IncontinenceUnited States
-
Sarfez Pharmaceuticals, Inc.Sarfez Pharmaceuticals, Inc.Recruiting
-
Sarfez Pharmaceuticals, Inc.CompletedChronic Kidney Diseases | Congestive Heart FailureIndia
-
Sarfez Pharmaceuticals, Inc.Completed
-
University of CincinnatiTerminatedAssessment of Coronary Flow Reserve in Heart Failure Patients After Ultrafiltration Versus DiureticsAcute Decompensated Heart FailureUnited States
-
Sarfez Pharmaceuticals, Inc.UnknownBody Weight ChangesIndia
-
VA Office of Research and DevelopmentRecruitingHypertension | Chronic Kidney DiseaseUnited States
-
Seoul National University HospitalCompletedHypertensionKorea, Republic of
-
Par Pharmaceutical, Inc.AnapharmCompletedTo Determine Bioequivalence Under Fasting Conditions
-
Yale UniversityActive, not recruitingHeart FailureUnited States